REGENXBIO Inc. Files 8-K: Corporate Updates
Ticker: RGNX · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1590877
Sentiment: neutral
Topics: corporate-filing, 8-K
Related Tickers: RGX
TL;DR
REGENXBIO filed an 8-K on 8/18/25 with corporate info. Nothing major disclosed.
AI Summary
REGENXBIO Inc. filed an 8-K on August 18, 2025, reporting other events and financial statements. The filing details the company's principal executive offices located at 9804 Medical Center Drive, Rockville, Maryland, 20850, and its telephone number as (240) 552-8181. This report is filed under the 1934 Securities Exchange Act.
Why It Matters
This 8-K filing provides essential corporate information and updates for REGENXBIO Inc., which is crucial for investors and stakeholders to stay informed about the company's operational status and reporting requirements.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information about significant financial events, acquisitions, or regulatory actions that would typically increase risk.
Key Players & Entities
- REGENXBIO Inc. (company) — Registrant
- August 18, 2025 (date) — Date of Report
- 9804 Medical Center Drive (location) — Principal Executive Offices Street
- Rockville, Maryland (location) — Principal Executive Offices City and State
- 20850 (location) — Principal Executive Offices Zip Code
- (240) 552-8181 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for REGENXBIO Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of August 18, 2025.
When was this 8-K report filed by REGENXBIO Inc.?
This 8-K report was filed on August 18, 2025.
What is the address of REGENXBIO Inc.'s principal executive offices?
The address of REGENXBIO Inc.'s principal executive offices is 9804 Medical Center Drive, Rockville, Maryland, 20850.
What is REGENXBIO Inc.'s telephone number?
REGENXBIO Inc.'s telephone number is (240) 552-8181.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-08-18 17:10:27
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share RGNX The Nasdaq Global Se
Filing Documents
- rgnx-20250818.htm (8-K) — 45KB
- rgnx-ex99_1.htm (EX-99.1) — 26KB
- img101737798_0.jpg (GRAPHIC) — 15KB
- 0000950170-25-109829.txt ( ) — 202KB
- rgnx-20250818.xsd (EX-101.SCH) — 24KB
- rgnx-20250818_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events. On August 18, 2025, REGENXBIO Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has extended the Prescription Drug User Fee Act ("PDUFA") date for the Company's Biologics License Application seeking accelerated approval of clemidsogene lanparvovec (RGX-121) for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome. The FDA extended the PDUFA action date from November 9, 2025 to February 8, 2026 to allow for the review of additional data. A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated August 18, 2025. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REGENXBIO INC. Date: August 18, 2025 By: /s/ Patrick J. Christmas II Patrick J. Christmas II Executive Vice President, Chief Strategy & Legal Officer